Summary
From January 1980 to August 1982 the Cancer and Leukemia Group B conducted a prospective randomized trial comparing chemoendocrine therapy with T-CAF (cyclophosphamide, adriamycin, and 5-fluorouracil plus tamoxifen) to CAF alone in postmenopausal women with advanced breast cancer. The patients were stratified by estrogen receptor (ER) status into three groups: ER-negative, ER-positive, ER-unknown. They were also stratified by dominant site of metastatic disease: visceral and other (osseous and/or soft tissue). A total of 246 eligible patients were enrolled in the study; 232 were evaluable and constitute the basis for this report. The study revealed that there was no difference in overall response frequency or response duration between T-CAF and CAF; there was no difference in response between T-CAF and CAF in ER-positive or in ER-negative patients; and there was no difference in response between T-CAF and CAF by dominant site of metastatic disease. The expected advantage of T-CAF over CAF, especially for ER-positive patients, was not observed.
This is a preview of subscription content, log in via an institution to check access.
References
Kardinal CG: Chemotherapy.In WL Donegan, JS Spratt (eds). Cancer of the Breast. Saunders, Philadelphia, 1979, pp 405–447
Greenspan EM, Fieber M, Lesnick G, Edelman S: Response of advanced breast carcinoma to the combination of the antimetabolite, methotrexate, and the alkylating agent, thiotepa. J Mt Sinai Hosp 30:246–267, 1963
Cooper R: Combination chemotherapy in hormone resistant breast cancer (Abstract). Proc Am Assoc Cancer Res 10:15, 1969
Kardinal CG, Donegan WL: Endocrine and hormonal therapy.In WL Donegan, JS Spratt (eds). Cancer of the Breast. Saunders, Philadelphia, 1979, pp 361–404
Greene GL, Jensen EV: The use of monoclonal antibodies in estrogen receptor assays (Abstract). Proc 13th Int Cancer Congress, Seattle, Washington, September 8–15, 1982, p 573
Mercer WD, Lippman ME, Wahl TM, Carlson CA, Wahl DA, Legotte D, Teague PO: The use of immunocytochemical techniques for the detection of steroid hormones in breast cancer cells. Cancer 46:2859–2868, 1980
Hilf R, Wittliff JL, Rector WD, Savlov ED, Hall TC, Orlando RA: Studies on certain cytoplasmic enzymes and specific estrogen receptors in human breast cancer and in nonmalignant diseases of the breast. Cancer Res 33:2054–2062, 1973
Lippman ME, Allegra JC: Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46:2829–2834, 1980
Cocconi G, DeLisa V, Mori P, Malacarne P, Amadori D, Giovanelli E: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: a randomized study. Cancer 51:581–588, 1983
Mouridsen HT, Palshof T, Engelsman E, Sylvester R: CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.In HT Mouridsen, T Palshof (eds). Breast Cancer — Experimental and Clinical Aspects. Pergamon Press, Oxford, 1980, pp 119–123
Ahmann FR, Jones SE, Moon TE, Davis SL, Salmon SE: Improved survival of patients with advanced breast cancer treated with adriamycin-cyclophosphamide plus tamoxifen (TAC) (Abstract). Proc AACR/ASCO 22:148, 1981
Tormey DC, Falkson HC, Falkson G, Voelkel J, Crowley J, Davis TE: Dibromoducitol and adriamycin ± tamoxifen in advanced breast cancer. Am J Clin Oncol 5:33–39, 1982
Osborne CK: Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat 1:121–123, 1981
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Kardinal, C.G., Perry, M.C., Weinberg, V. et al. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study. Breast Cancer Res Tr 3, 365–371 (1983). https://doi.org/10.1007/BF01807589
Issue Date:
DOI: https://doi.org/10.1007/BF01807589